Skip to content
Open access

Clinicopathologic and Molecular Features of H3 K27M-Mutant Diffuse Midline Glioma Across the Age Spectrum

Nov 2026 · Medicina · 0 citations · 43 references

Abstract

Background and Objectives: Diffuse midline glioma (DMG), H3 K27-altered, occurs in children and adults, but age-group differences and their prognostic significance remain uncertain. We examined clinicopathologic and molecular features and survival in H3 K27M-mutant DMG across age groups. Materials and Methods: This retrospective single-center study included 53 patients (18 children and 35 adults). Histologic features, treatment, targeted sequencing results (28 tumors), and overall survival (OS) were analyzed. Results: Thalamic tumors predominated in adults (77.1%) and brainstem tumors in children (66.7%; p < 0.001). Median Ki-67 labeling index (LI) was higher in children (39% vs. 20%; p = 0.032); the estimated age-group difference remained similar after adjustment for location. Treatment regimens differed by age, but no significant age-group differences were found in other histologic features or the genomic alterations examined. At the data cutoff, 48 patients (90.6%) had died. Median OS was 20.3 months, without a significant difference between children and adults (15.2 vs. 21.7 months; p = 0.124). Higher Ki-67 LI remained associated with shorter OS after adjustment for age group, brainstem involvement, necrosis, and upfront radiotherapy (hazard ratio (HR) 1.37 per 10-percentage-point increment; 95% confidence interval (CI), 1.16–1.63; p < 0.001). Necrosis was also independently associated with shorter OS (HR 2.54; 95% CI, 1.29–5.00; p = 0.007). TP53 alteration was associated with shorter OS in univariable analysis but not after adjustment. Conclusions: Age groups differed in anatomical distribution and proliferative activity, but age was not independently associated with OS. Ki-67 LI and necrosis may provide accessible prognostic information, whereas the association of TP53 alteration with outcome requires validation.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.